No Data
Kangtuo Healthcare: Summary of the 2024 Annual Report of Xi\'an Kangtuo Medical Technology Co., Ltd.
Kangtuo Healthcare: Xi\'an Kangtuo Medical Technology Co., Ltd. 2024 Annual Report
Xi\'an Kangtuo Medical Technology Co., Ltd. 2024 Annual Report
Summary of the 2024 Annual Report of Xi\'an Kangtuo Medical Technology Co., Ltd.
Kangtuo Medical (688314.SH): In 2024, the Net income is expected to increase by 17.07% year-on-year, proposing a dividend of 1.8 yuan per 10 shares.
On March 27, Gelonghui announced that Kangtuo Medical (688314.SH) released its annual report for 2024. During the reporting period, the company achieved revenue of 321.9452 million yuan, a year-on-year increase of 17.06%; the Net income attributable to the shareholders of the listed company was 88.3991 million yuan, a year-on-year increase of 17.07%; the Net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 74.8609 million yuan, a year-on-year increase of 9.52%, with major operational Indicators maintaining a steady growth trend. A cash dividend of 1.8 yuan per 10 shares will be distributed to all shareholders.
Kangtuo Medical (688314.SH): Currently, there is no complete Statistics on the penetration rate of PEEK material cranial repair products.
Gelonghui, on March 25, announced that Kangtuo Medical (688314.SH) stated on the investor interaction platform that there is currently no complete Statistics on the penetration rate of PEEK material cranial repair products. The intra-cranial pressure product of the company's affiliated company BRANCHPOINT & AURA DEVELOPMENT LLC has obtained FDA approval, and its registration in the domestic market is still in the preparation stage.